Median age was 60 years old (range 38-77). 37 patients had ECOG performance status (PS) 0-1 and 2 paients (5.1%) had ECOG PS 2. The response rate was 12.8% (5/39) ad the disease control rate was 48.7% (19/39). The median progression free survival (PFS) was 66 days (95% confidence inerval [CI], 47-84) and median overall survival (OS) was 147 days (95% CI, 116-238). The patients with a good response more than stable disease in 1st line therapy had longer overall survival (p = 0.019),and the patients with a good response in 2nd line therapy had longer progression free survival in third-line docetaxel chemotherapy (p = 0.029). A total of 130 cycles of chemotherapy (median 3, range 1-13) were administered and relative dose intensity was median 0.83 (range 0.49-1.00). There were hematologic toxicities including grade 3-4 neutropenia 17.9% (7/39), grade 3-4 thrombocytopenia 2.6% (1/39), and grade 3-4 anemia 12.8% (5/39). For non-hematologic toxicities, 2 patients (5.1%) had grade 3-4 infection, 2 ...
Low-Volume Disease. There is ongoing debate about how best to interpret the data generated by GETUG-AFU 15 and CHAARTED for men with low-volume disease. Although both trials failed to show an OS advantage with docetaxel in this subgroup, the CHAARTED study reported a tantalizing HR of 0.60 (95% CI, 0.32-1.13; P = .11).5 Longer follow-up is needed to see whether this promising signal will translate into a true OS benefit. Forthcoming data from STAMPEDE may also shed more light on this specific clinical question. Until then, there is insufficient evidence to strongly recommend the routine use of early docetaxel therapy for low-volume mHSPC, although it may still represent an appropriate choice for some men.. Controversy surrounds whether a negative subgroup analysis should strongly influence our interpretation of an otherwise significantly positive overall study. Knowing that the addition of docetaxel conferred such a substantial OS benefit in patients with high-volume disease, who comprised the ...
Docetaxel is an effective drug for the treatment of patients with several cancers, including non-small cell lung cancer (23, 24). However, tumor resistance to docetaxel therapy remains a major challenge. Quantitative [11C]docetaxel PET studies may provide insight in kinetics of docetaxel in tumors and therefore contribute to appropriate selection of cancer patients for docetaxel therapy. Using a state of the art validation approach, the present study shows the feasibility and reproducibility of quantitative PET studies with [11C]docetaxel in patients with lung cancer. Tumor kinetics of [11C]docetaxel were irreversible and associated with tumor perfusion. Patients pretreated with dexamethasone showed significantly lower [11C]docetaxel uptake in tumors, whereas no difference in [11C]docetaxel clearance was measured in these patients. In the few patients who were subsequently treated with docetaxel, [11C]docetaxel uptake in tumors seemed to be associated with treatment outcome.. [11C]docetaxel ...
The purpose of this study is to determine the efficacy of patupilone chemotherapy and to find out what effects (good and bad) the drug Patupilone has on
Docetaxel is a major drug in the treatment of metastatic breast cancer. In HER2 negative tumor, the first line treatment is based on docetaxel containing regimen: docetaxel alone, docetaxel + anthracycline or docetaxel + capecitabine. The efficacy of docetaxel in combination with trastuzumab has been demonstrated in first line metastatic breast cancer overexpressing erbB2 receptor. The response rate (RR) and the time to progression (TTP) observed were even higher than those obtained with paclitaxel +trastuzumab. Docetaxel is more and more used in first line metastatic setting, becoming the first Taxane used in this setting.As trastuzumab may raise safety/tolerability concerns, and as its interest in trastuzumab refractory patients may be limited, there is a need to find new drugs to combine with docetaxel in breast cancer, and to address the specific interaction/safety profile of this combination.The association of lapatinib and docetaxel will be the key combination in metastatic breast cancer ...
This trial will investigate the efficacy of neoadjuvant therapy with gimeracil/oteracil/tegafur and docetaxel in patients with advanced gastric cancer. The
In a phase 2 study of single-agent EC145 in heavily pretreated non-small cell lung cancer (NSCLC) patients (median of 3 prior chemotherapy regimens), the subgroup with all target lesions expressing the folate receptor [FR(++)] had a promising prolonged progression free survival of 7.1 months and overall survival of 10.9 months. Furthermore, in-vitro and in-vivo studies in KB models showed good synergism between EC145 and docetaxel.. This study will clinically assess for the first time the combination of EC145+docetaxel (Arm B) in participants with NSCLC (Stage IIIB or IV). This is an international, multicenter, centrally randomized, open-label, phase 2 study comparing single-agent EC145, EC145+docetaxel combination therapy, and single-agent docetaxel in participants with NSCLC who have failed one prior chemotherapy and who have all target lesions expressing the folate receptor [FR(++)]. Eligible participants will be randomized in a 1:1:1 ratio into either Arm A (single-agent EC145), Arm B ...
Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, relapse eventually occurs due to the development of resistance to docetaxel. To unravel the mechanism of acquired docetaxel resistance, we established docetaxel-resistant prostate cancer cells, TaxR, from castration-resistant C4-2B prostate cancer cells. The IC50 for docetaxel in TaxR cells was about 70-fold higher than parental C4-2B cells. Global gene expression analysis revealed alteration of expression of a total of 1,604 genes, with 52% being upregulated and 48% downregulated. ABCB1, which belongs to the ATP-binding cassette (ABC) transporter family, was identified among the top upregulated genes in TaxR cells. The role of ABCB1 in the development of docetaxel resistance was examined. Knockdown of ABCB1 expression by its specific shRNA or inhibitor resensitized docetaxel-resistant TaxR cells to docetaxel treatment by enhancing apoptotic cell death. Furthermore, we identified that apigenin, a ...
Purpose Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients. We investigate the impact of site of metastases on OS of a substantial sample of men with mCRPC who received docetaxel chemotherapy in nine phase III trials. Patients and Methods Individual patient data from 8,820 men with mCRPC enrolled onto nine phase III trials were combined. Site of metastases was categorized as lymph node (LN) only, bone with or without LN (with no visceral metastases), any lung metastases (but no liver), and any liver metastases. Results Most patients had bone with or without LN metastases (72.8%), followed by visceral disease (20.8%) and LN-only disease (6.4%). Men with liver metastases had the worst median OS (13.5 months). Although men with lung metastases had better median OS (19.4 months) compared with menwith liver metastases, they had ...
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung ...
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung ...
New Oral Formulation and in Vitro Evaluation of Docetaxel-Loaded Nanomicelles. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Single-agent docetaxel (Taxotere) has been shown to be highly active in metastatic breast cancer, with an overall response rate of 47%, median time to progression of 4 months, and survival of 10 months when administered as 1
Preclinical and phase II studies revealed that docetaxel is active against NSCLC. In chemotherapy-naïve patients with NSCLC response rates ranged from 19% to 54% with a median duration of survival ranging from 6.3 months to 11 months, and 1-year survival ranging from 21% to 71%. Docetaxel as single agent provided a survival as well as a clinical benefit over BSC in untreated patients with NSCLC. Docetaxel has been efficiently combined with cisplatin (ORR 33%-46%), carboplatin (ORR 30%-48%), vinorelbine (ORR 20%-51%), gemcitabine (ORR 37%-47%), with a median survival ranging from 5-14 months. A preliminary analysis of a multicenter randomized trial comparing docetaxel / CDDP with docetaxel / gemcitabine revealed that the two regimens had comparable activity in terms, of response rates, duration of response, TTP and overall survival; however, the docetaxel / gemcitabine combination has a most favourable toxicity profile compared to docetaxel / CDDP ...
Two agents blocking HER2 led to an additional six months of progression-free survival. Side effects were minimal with the addition of pertuzumab. Results published in the New England Journal of Medicine. SAN ANTONIO - Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients…
The antimitotic agent docetaxel is the standard therapy for patients with hormone-refractory prostate cancer (HRPC), but fatal resistance ultimately develops despite an initial response. Domingo-Domenech and colleagues generated docetaxel-resistant HRPC cell lines to gain insight into the underlying resistance mechanisms and identify potential targets to prevent the development of docetaxel resistance in HRPC. Docetaxel-resistant cells showed downregulation of epithelial differentiation markers such as cytokeratins (CK) and a marked upregulation of developmental genes in the Notch and Hedgehog signaling pathways. To determine whether these observations had clinical relevance, the authors evaluated a panel of primary and metastatic prostate cancer samples and identified a small subpopulation of preexisting CK-negative cells with upregulated Notch and Hedgehog signaling in each tumor. Of note, these cells were more abundant in samples from patients with advanced disease and a higher percentage of ...
For patients with non-small-cell lung cancer who have relapsed after initial treatment, the addition of the anti-angiogenesis drug ramucirumab to standard docetaxel chemotherapy extends survival.
Indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies.
Combination treatment of docetaxel chemotherapy and standard hormone therapy can be effective in men with advanced prostate that spreads outside the prostate gland.
To date, the targeting of FAK has faced significant challenges in the clinic. Early studies in ovarian cancer cell lines and xenografts demonstrated that knockdown of FAK expression enhanced docetaxel efficacy in docetaxel-sensitive and docetaxel-resistant models in vitro and in vivo (31, 32). Subsequently, TAE226, a TKI that targets FAK and IGF-1R, was demonstrated to enhance docetaxel cytotoxicity (33); however, at this point, development stalled due to the drug failing clinical trials. Other first-generation FAK TKIs had problems with compensatory upregulation of the FAK homolog, Pyk2, which affected clinical efficacy (34). Newer FAK TKIs targeting FAK and Pyk2, PF-00562271, and its second-generation PF-04554878, were well tolerated in phase I clinical trials (35, 36), and the latter is currently in phase Ib and II clinical trials (37). While the efficacy of combining PF-00562271 with cytotoxic agents has not been reported, coadministration of this TKI with sunitinib in a hepatocellular ...
Citations. Platelet lysate gel and endothelial progenitors stimulate microvascular network formation in vitro: tissue engineering implications. TM Fortunato, C Beltrami, C Emanueli, A Paul, G Pula - Scientific Reports, 2016, Article number: 25326 (2016)doi:10.1038/srep25326. Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy. Piwen WangEmail author, Susanne M. Henning, Clara E. Magyar, Yahya Elshimali, David Heber and Jaydutt V. Vadgama. Journal of Experimental & Clinical Cancer Research201635:73 DOI: 10.1186/s13046-016-0351-x. Aging Impairs VEGF-Mediated, Androgen-Dependent Regulation Of Angiogenesis. Laura Lecce1,2,*, Yuen Ting Lam1,2,*, Laura A. Lindsay2, Sui Ching Yuen1,2, Philippa J. L. Simpson1,2, David J. Handelsman2,3, andMartin K. C. Ng1,2,4 Mol Endorinl. 2014 Jul24 :,e20131405. Neuronal over-expression of ACE2 protects brain from ischemia-induced damage. Chen J, Zhao Y, Chen S, Wang J, Xiao X, Ma X, Penchikala M, Xia H, Lazartigues E, Zhao B, ...
Citations. Platelet lysate gel and endothelial progenitors stimulate microvascular network formation in vitro: tissue engineering implications. TM Fortunato, C Beltrami, C Emanueli, A Paul, G Pula - Scientific Reports, 2016, Article number: 25326 (2016)doi:10.1038/srep25326. Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy. Piwen WangEmail author, Susanne M. Henning, Clara E. Magyar, Yahya Elshimali, David Heber and Jaydutt V. Vadgama. Journal of Experimental & Clinical Cancer Research201635:73 DOI: 10.1186/s13046-016-0351-x. Aging Impairs VEGF-Mediated, Androgen-Dependent Regulation Of Angiogenesis. Laura Lecce1,2,*, Yuen Ting Lam1,2,*, Laura A. Lindsay2, Sui Ching Yuen1,2, Philippa J. L. Simpson1,2, David J. Handelsman2,3, andMartin K. C. Ng1,2,4 Mol Endorinl. 2014 Jul24 :,e20131405. Neuronal over-expression of ACE2 protects brain from ischemia-induced damage. Chen J, Zhao Y, Chen S, Wang J, Xiao X, Ma X, Penchikala M, Xia H, Lazartigues E, Zhao B, ...
Find out about the science and chemistry of Docetaxel (Taxotere), see colourful images of Docetaxel and explore interactive 3D molecules of Docetaxel
TY - JOUR. T1 - Phase I Trial of Intraperitoneal Docetaxel in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity. T2 - Dose-Limiting Toxicity and Pharmacokinetics. AU - Morgan, Robert J.. AU - Doroshow, James H.. AU - Synold, Timothy. AU - Lim, Dean. AU - Shibata, Stephen. AU - Margolin, Kim. AU - Schwarz, Roderich. AU - Leong, Lucille. AU - Somlo, George. AU - Twardowski, Przemyslaw. AU - Yen, Yun. AU - Chow, Warren. AU - Lin, Paul. AU - Paz, Benjamin. AU - Chu, David. AU - Frankel, Paul. AU - Stalter, Susan. PY - 2003/12/1. Y1 - 2003/12/1. N2 - Purpose: The purpose of this Phase I study was to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of i.p. docetaxel and to determine the peritoneal pharmacokinetics and pharmacological advantage of this agent. Experimental Design: Twenty-one patients with peritoneal carcinomatosis received docetaxel administered via an implanted i.p. catheter at doses of 40, 80, 100, 125, or 156 mg/m2 every 3 ...
May 20, 2008. Taxotere ® Generic Name: Docetaxel Link to Scientific American Article from 1996, discussing Taxoids (this is a PDF file). Drug Type: Taxotere is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Taxotere is classified as a plant alkaloid, a taxane and an antimicrotubule agent. (For more detail, see How Taxotere Works section below).…
Subjects will be randomized in a 1:1 ratio to receive CriPec docetaxel in cycle 1 and Taxotere in cycle 2 (Arm A) or Taxotere in cycle 1 and CriPec docetaxel in cycle 2 (Arm B). Both CriPec docetaxel and Taxotere will be administered at a dose of 75 mg/m2 (4-weekly, Q4W) and Taxotere at a dose of 75mg/m2 (3-weekly, Q3W). After completion of cycle 2, a radiographic evaluation will take place and the patients will go off study. Subjects without evidence of disease progression or drug related toxicity can continue treatment with Taxotere (75mg/m2, Q3W) according to local standard guidelines for Taxotere treatment until disease progression or unacceptable toxicity occurs ...
Taxotere was first approved by the U.S. Food and Drug Administration in 1996. The drug was approved to treat individuals with breast cancer, stomach cancer, prostate cancer, and non-small-cell lung cancer.. Taxotere affects cancer cells by disrupting the function of microtubules. These structures play a role in the replication of cancer cells. Taxotere essentially stops cancerous cells from functioning and dividing. This has made Taxotere a highly effective chemotherapy agent.. Despite its effectiveness, the chemotherapy drug has also caused patients some unexpected damages. Those suffering from Sanofi negligence alleged that the company failed to properly warn them - and their physicians - of these life-changing side effects.. It should be noted that docetaxel is the generic name of Taxotere. There are various products/forms which contain docetaxel including the "brand-name" chemotherapy drugs Docefrez and Docetaxel Injection.. ...
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment
When natural products meet cellular targets: A potential role of IGF-1 receptor in lycopene and docetaxel combination for prostate cancer therapy
Included within the scope of the present invention are potent taxanes and taxanes containing a linking group. Also included is a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for inducing cell death in selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient is also included. A method for inducing cell death in selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent is included as well.
Health,...DENVER and SAN CARLOS Calif. April 22 /- Nekt... ...In a comparative study of NKTR-105 and docetaxel NKTR-105 treatment s... ...,NKTR-105,Demonstrates,Superior,Antitumor,Activity,and,Improved,Pharmacokinetics,Over,Docetaxel,in,Preclinical,Studies,Presented,at,AACR,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
This trial is comparing the efficacy and quality-of-life effects of docetaxel, alone or in combination with ramucirumab, in patients with non-small cell lung
The relatively recent introduction of a new class of chemotherapeutic agents--the taxoids--has raised hope of improved survival for patients with advanced or metastatic cancer. Following encouraging preclinical results of taxoid combinations, this phase I, nonrandomized trial was designed to evaluate a 1-hour intravenous infusion of docetaxel (Taxotere) on day 1 combined with fluorouracil (5-FU) as a daily intravenous bolus for 5 consecutive days. 1
Docetaxel is a chemotherapy drug that is used in the treatment of several types of cancer. Chemotherapy treatments are also referred to as cytotoxic drugs, which means they are toxic and damaging to cells. Although these drugs are used to kill cancerous cells, they can also kill off healthy cells in the body.
Title: MedicineNet docetaxel Specialty, Description: MedicineNet docetaxel Specialty, By: Feedage Forager, ID: 331317, Grade: 88, Type: RSS20
For example, if you have 6 people for a test and 3 take Rogaine and 3 take a placebo, the results may not show what would happen on a larger scale. You could have 2 out of 3 people regrow their hair for reasons beyond what is being tested, the Rogaine after Taxotere. On the other hand, you could have 0 out of 3 people show any improvement, but that could be for a variety of reasons. You can see how small sample sizes for studies like this do not offer much useful information or much confidence in its findings. This is why many doctors just recommend that people try Rogaine after receiving Taxotere because is "might" work. Theres not much harm being done other than wasting a relatively small amount of time and money. Its important to note that that data does not show that it helps, nor does it show that it doesnt help. Unfortunately, until someone performs a well-conducted trial to see how Rogaine affects the hair loss thats all the information we have.. The only study I found that actually ...
Patient information for DOCETAXEL 160 MG/8 ML CONCENTRATE FOR SOLUTION FOR INFUSION Including dosage instructions and possible side effects.
Page contains details about example of docetaxel comprising stable nanocomposition . It has composition images, properties, Characterization methods, synthesis, applications and reference articles : nano.nature.com
Page contains details about example of docetaxel comprising stable nanocomposition . It has composition images, properties, Characterization methods, synthesis, applications and reference articles : nano.nature.com
WHITE PHARMACEUTICALS - Exporter, Importer, Distributor, Supplier, Trading Company of DOCETERE - DOCETAXEL based in New Delhi, India
...VIENNA Austria May 23 2007-The chemotherapy drugdocetaxel currentl...The use of chemotherapy to treat prostate cancer has rapidlygrown in ...The Medical University of Vienna has now carried out theworld¹s ...TWO DRUGS - ONE CLEAR RESULT The trial clearly demonstratedthe su...,Prostate,Cancer:,Clinical,Study,Demonstrates,Superior,Efficacy,of,Docetaxel,Chemotherapy,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
We assessed outcomes from men with metastatic castration-resistant prostate cancer that had spread to the liver and/or lungs in the PREVAIL clinical trial of enzalutamide in patients who had not received docetaxel chemotherapy. Compared with placebo, enzalutamide lengthened the time it took for the cancers to grow (according to changes in scans), prostate-specific antigen to rise, or patients to require chemotherapy. Background: The Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy (PREVAIL) trial was unique as it included patients with visceral disease. This analysis was designed to describe outcomes for the subgroup of men from PREVAIL with specific sites of visceral disease to help clinicians understand how these patients responded to enzalutamide prior to chemotherapy. Patients and Methods: Prespecified analyses ...
TY - JOUR. T1 - A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer. T2 - A gruppo oncologico italia meridionale study. AU - Vici, P.. AU - Giotta, F.. AU - Di Lauro, L.. AU - Sergi, D.. AU - Vizza, E.. AU - Mariani, L.. AU - Latorre, A.. AU - Pizzuti, L.. AU - DAmico, C.. AU - Giannarelli, D.. AU - Colucci, G.. PY - 2011/12. Y1 - 2011/12. N2 - Objective: To evaluate two docetaxel-based regimens as first-line treatment in advanced breast cancer patients. Methods: Patients were randomly assigned to docetaxel/gemcitabine (arm A: docetaxel 75 mg/m 2 on day 1, gemcitabine 1,000 mg/m 2 on days 1 and 8) or docetaxel/capecitabine (arm B: docetaxel 75 mg/m 2 on day 1, capecitabine 1,250 mg/m 2 twice daily on days 1-14); both chemotherapy regimens were repeated every 21 days. The primary objective of the study was to evaluate the response rate. Results: Seventy-two patients were enrolled (36 each in arms A and ...
In this study, we developed a cost-effectiveness simulation using a Markov model to evaluate the cost-effectiveness of 4 treatment strategies for men with advanced hormone-naive prostate cancer based on the STAMPEDE trial. The ICER of SOC plus zoledronic acid, SOC plus docetaxel, and SOC plus zoledronic acid/docetaxel were $100,802.75/QALY, $38,977.15/QALY, and $89,782.46/QALY, respectively, compared with SOC alone, indicating that SOC plus zoledronic acid, SOC plus docetaxel, and SOC plus zoledronic acid/docetaxel are unlikely to be cost-effective compared with SOC alone based on a WTP threshold of $20,301.00/QALY.. Although a significant OS improvement for ADT plus docetaxel versus ADT alone was seen in the STAMPEDE trial, which was consistent with the result of the CHAARTED-E3805 trial (24), the addition of docetaxel to ADT did not show a significant OS benefit versus ADT alone in the GETUG-AFU 15 trial (25). Discrepancies between the GETUG-AFU15 trial and the CHAARTED-E3805 or STAMPEDE ...
The US Food and Drug Administration (FDA) today gave the green light for abiraterone acetate to be used in combination with prednisone for the treatment of "castration-resistant" prostate cancer in patients who have received prior docetaxel chemotherapy. "Todays announcement marks the culmination of two decades of work at the ICR to design and develop this drug," ICR Chief Executive Professor Alan Ashworth says. "This very significant achievement underlines the importance of drug discovery work in the not-for-profit sector." Abiraterone acetate was invented by Professor Mike Jarman and his colleagues in what is now the Cancer Research UK Cancer Therapeutics Unit at the ICR in Sutton, south of London. Prostate cancer cells need the male hormone testosterone to grow, so the team set out to design a drug that would cut off the source of testosterone. The ICR continued research on abiraterone acetate with The Royal Marsden Hospital after licensing the drug to Ortho Biotech Oncology Research & ...
Background Several clinical trials have performed riskCbenefit analyses comparing docetaxel and pemetrexed or docetaxel and vinca alkaloid, but the efficacy and safety remain uncertain. neutropenia and febrile neutropenia ( em P /em 0.05), but there was no difference in non-hematological toxicity ( em P /em 0.05). Docetaxel led to a lower rate of anemia as first-line treatment ( em P /em 0.05). Moreover, docetaxel caused less grade 3/4 hematological and non-hematological toxicity compared with vinca alkaloid. Conclusion Docetaxel leads to a better result than vinca alkaloid in effectiveness and safety on patients with advanced non-small-cell lung cancer as first-line therapy. Docetaxel also causes lower toxicity as second-line therapy compared with vinca alkaloid. However, the differences in efficacy and safety PD0325901 manufacturer between docetaxel and pemetrexed are not obvious. Further clinical study with more details, such as sex, age, histology, and so on, should be considered for ...
The trial was done at The Ohio State University and University of Colorado. MBC patients over the age of 18 years with histologically proven breast cancer with evidence of MBC and the following characteristics were eligible: The presence of at least one metastatic site measurable by Response Evaluation Criteria in Solid Tumors (15), Eastern Cooperative Oncology Group performance status ≤2, leukocytes ≥3,000/μL, absolute neutrophil count ≥1,500/μL, platelets ≥ 100,000/μL, total bilirubin ≤ institutional upper limit of normal, transaminases ≤2.5 times upper limit of normal, and creatinine ≤ upper limit of normal or creatinine clearance ≥60 mL/min for patients with creatinine above upper limit of normal. No more than one prior chemotherapy regimen for MBC was permitted. In the event that prior therapy contained a taxane, at least 6 months must have elapsed since completing prior taxane treatment. Written informed consent was required and the institutional review boards of the ...
Taxotere is a chemotherapy drug used in the treatment of most cancers especially breast cancer. The objective of most chemotherapy drugs is to eradicate or slow down the growth of cancer cells without the risk of permanent side effects. Taxotere is associated with a wide range of side effects but one such consequence has been a subject of defective drug lawsuits against Sanofi Aventis, the manufacturer of Taxotere.. In a survey involving cancer patients, taxotere caused bone pain and muscle aches. Some claim that their arms and legs ache while others feel pain in their neck, back, and shoulder. Taxotere is also associated with neuropathy resulting to numbness and a tingy feeling in the feet and hands. It may also cause diarrhea, stomatitis, thinning of nails, and nail hyperpigmentation. The side effects of taxotere are individual and dosage dependent.. One of the most controversial side effects of taxotere that has put its manufacturer Sanofi Aventis in hot water is permanent alopecia. Although ...
Taxane-induced peripheral neuropathy (TIPN) is a main toxicity of taxanes with no effective treatment. This study aimed to compare the efficacy and safety of pr...
This study is the first to demonstrate that reduced p27 expression is associated with acquired resistance to docetaxel in breast cancer cells in vitro. There may be several mechanisms that are involved in this process and that may be the result of either transcriptional or translational regulation, with modulation of gene expression and/or resultant production of the protein. In addition, there may be an increased degradation of p27 via the ubiquitin degradation pathway.. Previous studies have indicated that decreased expression of p27 is associated with drug resistance to hormonal therapy (e.g. tamoxifen) in breast cancer cells and to chemotherapy (e.g. cisplatin in malignant gliomas), mediated through mitogen-activated protein kinase activation [20, 21, 33]. It has also been reported that reduced p27 protein expression in epithelial ovarian tumours was observed, as compared with normal ovaries, from patients receiving cisplatin and paclitaxel treatment [34]. Reduced p27 expression was ...